McKesson (NYSE:MCK) agreed to acquire Precision Medicine Group for approximately $2.25 billion, adding clinical research and biopharma commercialization services to its oncology and multispecialty operations.
Summit Therapeutics (NASDAQ:SMMT) announced publication of primary analysis results from the Phase III HARMONi clinical trial, showing ivonescimab combined with chemotherapy improved progression-free survival in patients with EGFR-mutated advanced non-small cell lung cancer.
Johnson & Johnson (NYSE:JNJ) received U.S. Food and Drug Administration approval for IMAAVY (nipocalimab-aahu) as the first treatment specifically approved for warm autoimmune hemolytic anemia (wAIHA) in adults and pediatric patients aged 12 years and older.
Molecular Partners (NASDAQ:MOLN) reported first-half 2026 results and clinical progress across its oncology pipeline, including MP0712, a DLL3-targeting Radio-DARPin program for small cell lung cancer that advanced into the next trial cohort.
Rhythm Pharmaceuticals (NASDAQ:RYTM) received Japanese marketing authorization for its IMCIVREE therapy, targeting a company-estimated 5,000 to 8,000 obesity patients.
REGENXBIO (NASDAQ:RGNX) reported that the U.S. Food and Drug Administration placed a clinical hold on its investigational MPS II gene therapy RGX-121 following spine MRI findings in five participants in the CAMPSIITE study.
Monte Rosa Therapeutics (NASDAQ:GLUE) announced that the first patient has been dosed in MODeFIRe-1, a Phase 2 trial evaluating investigational molecular glue degrader MRT-2359 with apalutamide in patients with AR mutation-positive metastatic castration-resistant prostate cancer.
VERAXA Biotech (NASDAQ:VRXA) and Secarna Pharmaceuticals announced a research milestone in their collaboration to develop antibody-oligonucleotide conjugates for autoimmune and chronic immune diseases.
TwinStrand Biosciences announced that the U.S. District Court for the District of Delaware entered final judgment in favor of TwinStrand and the University of Washington in their patent infringement case against Guardant Health (NASDAQ:GH), awarding more than $245.2 million in damages, royalties, and interest.
Spruce Biosciences (NASDAQ:SPRB) announced that it completed two pre-BLA meetings with the U.S. Food and Drug Administration supporting its planned submission of a Biologics License Application for tralesinidase alfa enzyme replacement therapy in Sanfilippo Syndrome Type B.
Insmed (NASDAQ:INSM) announced that Japan’s Ministry of Health, Labour and Welfare approved BRINSUPRI (brensocatib 25 mg) for adults and pediatric patients aged 12 years and older with non-cystic fibrosis bronchiectasis.
BriaCell (NASDAQ:BCTX) announced that Bria-MEL+ has passed a key genetic engineering milestone, moving the personalized whole-cell melanoma immunotherapy vaccine candidate toward potential clinical development.
